While biotech companies are some of the largest disruptors in the broader healthcare sector, broad healthcare indexes tend to lack concentrated biotech exposure. As such, for investors choosing to follow an index strategy, the author of today’s article highlights two indexes that offer exposure to biotech stocks that have one or more drugs in Phase II and Phase III U.S. FDA trials, noting “This strategy reduces the likelihood of early-stage failures in preclinical or Phase I trials, while still leaving potential for stock price growth once the drug is officially approved.” For more, CLICK HERE.